The Management of Lymphoma in the Setting of Pregnancy.


:The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors, of which the most influential are the trimester at diagnosis, the stage, and aggressiveness of the disease and the presence of life-threatening symptoms. Recent data suggest that deferral of therapy until after the first trimester is desirable if it is perceived that postponement of therapy will not compromise maternal outcome. For some patients, delay of therapy to the postpartum period is feasible.


Curr Hematol Malig Rep


Pinnix CC,Andraos TY,Milgrom S,Fanale MA




Has Abstract


2017-06-01 00:00:00














  • The role of parenteral nutrition in acute leukemia.

    abstract::Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Jacobson NB,Parekh N,Kalaycio M

    更新日期:2006-09-01 00:00:00

  • Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.

    abstract:PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Kennedy JA,Hobbs G

    更新日期:2018-06-01 00:00:00

  • Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

    abstract::Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criter...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Steensma DP

    更新日期:2012-12-01 00:00:00

  • Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.

    abstract::Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Kahl BS

    更新日期:2009-10-01 00:00:00

  • New aspects of the treatment of chronic lymphocytic leukemia.

    abstract::Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Faderl S,Wierda W,Keating MJ

    更新日期:2006-12-01 00:00:00

  • Contemporary treatment of APL.

    abstract::Acute promyelocytic leukemia (APL) is characterized by coagulopathy, leukopenic presentation and sensitivity to anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). For the last 25 years, APL has been treated with a combination of ATRA and chemotherapy for induction followed by consolidation and ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Cull EH,Altman JK

    更新日期:2014-06-01 00:00:00

  • Quality of life in MPN comes of age as a therapeutic target.

    abstract::BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Scherber RM,Geyer HL,Mesa RA

    更新日期:2014-12-01 00:00:00

  • Update on antigen-specific immunotherapy of acute myeloid leukemia.

    abstract::Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Buckley SA,Walter RB

    更新日期:2015-06-01 00:00:00

  • Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it?

    abstract::Haploidentical hematopoietic stem cell transplantation (HSCT) using mismatched family member donors has historically been complicated by high rates of nonrelapse toxicity and the need for laboratory expertise in depleting grafts of T lymphocytes. Over the past decade, improvements in supportive care, the increased use...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Hale GA

    更新日期:2007-07-01 00:00:00

  • Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.

    abstract::Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the n...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Betcher J,Dow E,Khera N

    更新日期:2016-08-01 00:00:00

  • Targeting chronic myeloid leukemia stem cells.

    abstract::Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Helgason GV,Young GA,Holyoake TL

    更新日期:2010-04-01 00:00:00

  • Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

    abstract::Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Karp Leaf R,Cho HJ,Avigan D

    更新日期:2015-12-01 00:00:00

  • Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

    abstract:PURPOSE OF REVIEW:To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS:Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognosti...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Mina AA,Stein B

    更新日期:2019-06-01 00:00:00

  • The Future of Targeting FLT3 Activation in AML.

    abstract::Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Leick MB,Levis MJ

    更新日期:2017-06-01 00:00:00

  • Artificial Intelligence in Hematology: Current Challenges and Opportunities.

    abstract:PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Radakovich N,Nagy M,Nazha A

    更新日期:2020-06-01 00:00:00

  • Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

    abstract:PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Torka P,Barth M,Ferdman R,Hernandez-Ilizaliturri FJ

    更新日期:2019-10-01 00:00:00

  • Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation.

    abstract::C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Callejas-Díaz A,Gea-Banacloche JC

    更新日期:2014-03-01 00:00:00

  • High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

    abstract::Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Gergis U,Wissa U

    更新日期:2010-01-01 00:00:00

  • Polatuzumab Vedotin: a New Target for B Cell Malignancies.

    abstract:PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Choi Y,Diefenbach CS

    更新日期:2020-04-01 00:00:00

  • Choosing Wisely® in Hematology: Have We Made a Difference?

    abstract:PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Hilal T,Munoz J

    更新日期:2020-08-01 00:00:00

  • Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

    abstract:PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Chander U,Leeman-Neill RJ,Bhagat G

    更新日期:2018-08-01 00:00:00

  • Chemotherapy for patients with acute myeloid leukemia in first remission.

    abstract::Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Bradstock K

    更新日期:2006-06-01 00:00:00

  • The GHSG Approach to Treating Hodgkin's Lymphoma.

    abstract::Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Bröckelmann PJ,Engert A

    更新日期:2015-09-01 00:00:00

  • Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?

    abstract::Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Forstpointner R,Dreyling M

    更新日期:2011-12-01 00:00:00

  • Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?

    abstract::The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Casasnovas RO,Meignan M,Berriolo-Riedinger A,Itti E,Huglo D,Haioun C,Morschhauser F

    更新日期:2012-09-01 00:00:00

  • Lenalidomide in myelodysplastic syndromes: where do we go from here?

    abstract::Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章


    authors: Sirulnik LA,Stone RM

    更新日期:2008-01-01 00:00:00

  • Cutaneous T-cell lymphoma: Biologic targets for therapy.

    abstract::Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrat...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Choi J,Foss F

    更新日期:2007-10-01 00:00:00

  • Navigating Ethical Practices in the Era of High Cost Hematology.

    abstract:PURPOSE OF REVIEW:In this review article, we will highlight ethical issues faced by hematologists due to a growing constellation of expensive diagnostics and therapeutics in hematology. We outline the important issues surrounding this topic including stakeholders, cost considerations, and various ethical challenges sur...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Ertz-Archambault N,Khera N

    更新日期:2020-10-01 00:00:00

  • Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.

    abstract::The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章


    authors: La Rosée P,Hochhaus A

    更新日期:2008-04-01 00:00:00

  • Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.

    abstract::Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审


    authors: Chung CG,Poligone B

    更新日期:2015-12-01 00:00:00